MedCity News December 4, 2023
Frank Vinluan

Eli Lilly’s Jaypirca is now approved for treating three types of blood cancers. While Jaypirca blocks a target already addressed by other cancer therapies, the Lilly molecule does it in a way that sets it apart from the rest of its drug class.

Eli Lilly cancer drug Jaypirca is closing 2023 the same way it started—with an FDA approval. The latest regulatory nod adds two additional types of blood cancers to the list of indications for the therapy.

Friday’s accelerated approval for Jaypirca covers the treatment of adults with either chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The once-daily oral drug is a small molecule designed to block Bruton’s tyrosine kinase, or BTK, a cancer-driving enzyme. While other...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
Latigo raises $150M to get non-opioid pain drugs through key tests
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
CMS doubles down on Medicare drug price negotiations
Drug shortages could surge 25% as AI reshapes specialty pharmacy: Survey

Share This Article